Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?

  1. Matthew C. Riddle1⇑ and
  2. William T. Cefalu2
  1. 1Division of Endocrinology, Diabetes, & Clinical Nutrition, Oregon Health & Science University, Portland, OR
  2. 2American Diabetes Association, Arlington, VA
  1. Corresponding author: Matthew C. Riddle, riddlem{at}ohsu.edu.
Diabetes Care 2018 Dec; 41(12): 2444-2447. https://doi.org/10.2337/dci18-0041
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In the recent past we have been fortunate to find new treatments based on entirely new mechanisms . . . or is that really so? The sodium–glucose cotransporter inhibitors (SGLTi) offer an instructive case in point. These apparently “new” agents were preceded by phlorizin, a naturally occurring compound that has been used for physiologic studies for over 100 years (1). Given orally it interferes with intestinal absorption of carbohydrates and causes glucosuria. Studies in animal models of diabetes have provided useful insights, such as evidence that reduction of hyperglycemia can restore insulin sensitivity toward normal (2). However, phlorizin was considered unsuited for use by humans due to undesirable side effects. Recently its mechanism of action has been traced to effects on sodium–glucose cotransporters (SGLT) in the intestinal mucosa and the renal proximal tubule (3), and drugs with more nuanced effects on these transporters have been developed (4,5). These newer agents have greater affinity for SGLT2, which is expressed mainly in the kidney, and less for SGLT1, which facilitates intestinal absorption of glucose. Clinical effects of the newer SGLTi drugs in type 2 diabetes (T2D) include modest reductions of plasma glucose and A1C, weight, and blood pressure and are mediated in large part by glucosuria and sodium diuresis. These agents are taken once daily by mouth and do not require dose titration. Symptomatic side effects—mostly urinary or genital irritation or infections—are common but tolerated by most patients.

Importantly, the new SGLTi drugs have highly desirable—and somewhat unexpected—cardiac and renal protective effects, as least in selected cohorts. Large trials of empagliflozin and canagliflozin, aiming to demonstrate safety in patients with T2D and high cardiovascular risk, have shown favorable effects on heart failure, cardiovascular death, and progression of albuminuria (6–9). Unwanted effects have been reported as well, including dehydration, lower-extremity amputations, and diabetic ketoacidosis (DKA), but they are relatively uncommon.

Although their underlying mechanisms are not fully understood, the cardiovascular and renal benefits have led to great enthusiasm for the SGLTi drugs and increasing clinical use. Consideration of their use immediately after metformin is advised for patients with T2D with established cardiovascular disease (10), and questions have arisen about other groups of patients. We need to know whether these agents can be as effective for patients with T2D not accompanied by overt cardiovascular or renal disease, or for cardiac patients without diabetes, and studies are exploring these questions. But what about prescribing these agents along with basal-bolus insulin for type 1 diabetes (T1D) (11)?

Supplementing earlier small studies of combining an SGLTi with basal-bolus insulin for T1D, six reports of larger studies have now been published (12–17), two of them in this issue (16,18) and three in the September issue of Diabetes Care (14,15,17). These studies were designed to determine whether this form of combination therapy can improve glycemic control without unacceptable risk of hypoglycemia, DKA, or other immediately apparent adverse effects in this population. Their main features and results are summarized in Table 1. Canagliflozin was the drug used in one study, sotagliflozin in three, dapagliflozin in two, and empagliflozin in one. The designs of these studies were similar. All were two- or three-arm, randomized, placebo-controlled studies with duration between 18 and 52 weeks. The mean age of participants was between 41 and 46 years, mean BMI between 27 and 30 kg/m2, and mean baseline A1C between 7.6 and 8.5%. Outcomes reported at the end of the studies were also similar. The mean placebo-adjusted improvement of A1C associated with use of the SGLTi ranged between 0.25 and 0.52%, with little difference between lower and higher doses in the studies that included this comparison. Changes of weight relative to placebo averaged between −2.2 and −4.4 kg, with a tendency toward greater reductions at the higher doses. Of note was the incidence of DKA, which ranged between 1.5 and 6.0% greater with active treatment than with placebo. Other than DKA, no notable adverse effects beyond the urogenital symptoms previously observed in T2D appeared in these short-term studies.

View this table:
  • View inline
  • View popup
Table 1

Design features and main outcomes of large randomized clinical trials evaluating efficacy and safety of SGLTi in T1D

How can we interpret these results? On the positive side, the reduction of A1C by about 0.3–0.4% (1.5–2.0 mmol/mol) is at a level generally considered clinically significant. If sustained over time, this improvement would likely reduce the risk of microvascular complications. Better overall control was obtained without increasing the risk of hypoglycemia. The modest but consistent reduction of weight might also be important for some patients and could limit later cardiovascular risk. These considerations are naturally appealing to patients and providers who are frustrated when glycemic targets cannot be attained and concerned about weight and other cardiovascular risk factors.

Unfortunately, there are also limitations. The increased frequency of DKA is the main cause for concern. The incidence of confirmed DKA averaging close to 3% during these studies lasting no longer than a year is not a trivial problem. This risk might be even greater under conditions in routine clinical settings where monitoring of patients may be less close than in clinical trials. Experience in populations of patients considered to have T2D has shown that treatment with an SGLTi can be associated with DKA accompanied by no more than moderate hyperglycemia and nonspecific symptoms (19–21). In many cases the event is preceded by an illness or procedure or by an inappropriate reduction of insulin dosage. The correct diagnosis may be delayed by lack of marked hyperglycemia. Some patients affected clearly have T2D, but many appear to be individuals with unrecognized T1D. Thus, the consistently increased frequency of DKA in recent studies of SGLTi in T1D is not very surprising. If SGLTi drugs are to be approved and prescribed for T1D, heightened awareness about this complication must be emphasized. This is also true for patients thought to have T2D who actually have T1D and are already being prescribed SGLTi, especially given recent reports of increasingly frequent hospital admissions for DKA generally (22,23). Education and support of both patients and medical providers to prevent euglycemic DKA are key clinical strategies and must be improved. They should include advice on ketone testing as well as recognition of atypical symptoms (nausea, vomiting, malaise) in the absence of significant hyperglycemia (24).

Moreover, even if we are able to limit the risk of DKA, there are other questions to address. Is the excess of fractures found in the canagliflozin development studies in T2D (25), posing the possibility of a class effect of SGLTi on bone integrity, a real concern? No such effect has yet been seen with empagliflozin and dapagliflozin (26,27), but physiologic studies of bone metabolism provide some support for this hypothesis (28–30). In addition to altered handling of calcium and phosphorus in the kidney, ongoing mobilization of gluconeogenic substrates provoked by fasting glucosuria and accompanying hormonal changes might lead to a long-term effect on bone matrix. Weight loss due to caloric restriction is known to be associated with loss of bone mineral and fractures (31–33), and women with anorexia nervosa have greatly reduced bone mineral content at an early age (34,35). Whether long-term use of SGLTi drugs by younger T1D patients could have effects on bone like those induced by voluntary dietary restriction cannot be determined by short-term studies. We need to weigh known short-term clinical benefits against potential long-term risks such as this one.

These observations on the efficacy and safety of SGLTi have important clinical implications. Balancing benefits versus risks of SGLTi will require thoughtful decisions by regulatory and professional groups, care providers, and also people with diabetes. The most obvious responsibility falls upon regulators and groups creating guidance for clinical care. Does the evidence provided by these short-term studies justify approval of these agents for use in T1D? If so, what tactics for mitigation of risks are needed? Are we at a stage where we can stratify individual patients according to benefits versus risks so as to allow appropriate use of these new drugs by selected cohorts? We can expect a vigorous discussion of these questions. To support such decisions, we need more information. Of particular interest is whether a direct renal effect limiting progression of nephropathy—beyond that provided by improved control of A1C and blood pressure—can be demonstrated in T1D, and the present studies do not address this question. Also, confirmation of the short-term risk of DKA in T1D reminds us that long-term risks also need further evaluation in both T1D and T2D. As suggested in earlier commentaries (36–38), drugs in this class should be prescribed cautiously until longer-term, prospectively collected experience with them is available.

The story that began with phlorizin is still in progress. The newer SGLTi drugs offer a greatly improved balance of benefits versus risks, and their use in T1D is clearly an exciting possibility. It would offer the first adjunctive oral therapy for this important cohort of patients. But we do need more information to personalize the use of these powerful new agents in T1D. So, is use of SGLTi agents in T1D “an obvious choice,” or are the promises of this approach “too good to be true”? The key lies in precise identification of which patients will obtain the greatest benefit with the least risk.

Article Information

Funding and Duality of Interest. No commercial sponsors contributed support. Financial support was provided in part by the Rose Hastings and Russell Standley Memorial Trusts. M.C.R. reports receiving research grant support through Oregon Health & Science University from Novo Nordisk and AstraZeneca and honoraria for consulting from Adocia, AstraZeneca, Dance, Elcelyx, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Sanofi, and Theracos. These potential dualities of interest have been reviewed and managed by Oregon Health & Science University. W.T.C. is an employee of the American Diabetes Association. No other potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying articles, pp. 2552 and 2560.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    Ehernkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31–38
  2. ↵
    1. Rossetti L,
    2. Smith D,
    3. Shulman GI,
    4. Papachristou D,
    5. DeFronzo RA
    . Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510–1515pmid:3571496
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Ferrannini E
    . Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 2017;26:27–38pmid:28506519
    OpenUrlPubMed
  4. ↵
    1. Chao EC,
    2. Henry RR
    . SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551–559pmid:20508640
    OpenUrlCrossRefPubMed
  5. ↵
    1. Scheen AJ
    . Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33–59pmid:25488697
    OpenUrlCrossRefPubMed
  6. ↵
    1. Zinman B,
    2. Wanner C,
    3. Lachin JM, et al.; EMPA-REG OUTCOME Investigators
    . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128pmid:26378978
    OpenUrlCrossRefPubMed
    1. Neal B,
    2. Perkovic V,
    3. Mahaffey KW, et al.; CANVAS Program Collaborative Group
    . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657pmid:28605608
    OpenUrlCrossRefPubMed
    1. Abdul-Ghani M,
    2. Del Prato S,
    3. Chilton R,
    4. DeFronzo RA
    . SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME trial. Diabetes Care 2016;39:717–725pmid:27208375
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Heerspink HJL,
    2. Kosiborod M,
    3. Inzucchi SE,
    4. Cherney DZI
    . Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018;94:26–39pmid:29735306
    OpenUrlPubMed
  8. ↵
    1. American Diabetes Association
    . 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S73–S85pmid:29222379
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Dellepiane S,
    2. Ben Nasr M,
    3. Assi E, et al
    . Sodium glucose cotransporters inhibitors in type 1 diabetes. Pharmacol Res 2018;133:1–8pmid:29689314
    OpenUrlPubMed
  10. ↵
    1. Henry RR,
    2. Thakkar P,
    3. Tong C,
    4. Polidori D,
    5. Alba M
    . Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 2 diabetes. Diabetes Care 2015;38:2258–2265pmid:26486192
    OpenUrlAbstract/FREE Full Text
    1. Garg SK,
    2. Henry RR,
    3. Banks P, et al
    . Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337–2348pmid:28899222
    OpenUrlCrossRefPubMed
  11. ↵
    1. Buse JB,
    2. Garg SK,
    3. Rosenstock J, et al
    . Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care 2018;41:1970–1980pmid:29937430
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Danne T,
    2. Cariou B,
    3. Banks P, et al
    . HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem study. Diabetes Care 2018;41:1981–1990pmid:29937431
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Dandona P,
    2. Mathieu C,
    3. Phillip M, et al.; DEPICT-1 Investigators
    . Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care 2018;41:2552–2559
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Mathieu C,
    2. Dandona P,
    3. Gillard P, et al.; DEPICT-2 Investigators
    . Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 2018;41:1938–1946pmid:30026335
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Rosenstock J,
    2. Marquard J,
    3. Laffel LM, et al.
    Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 2018;41:2560–2569
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Taylor SI,
    2. Blau JE,
    3. Rother KI
    . SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849–2852pmid:26086329
    OpenUrlCrossRefPubMed
    1. Peters AL,
    2. Buschur EO,
    3. Buse JB,
    4. Cohan P,
    5. Diner JC,
    6. Hirsch IB
    . Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687–1693pmid:26078479
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Meyer EJ,
    2. Gabb G,
    3. Jesudason D
    . SGLT2 inhibitor–associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and spontaneous adverse event notifications. Diabetes Care 2018;41:e47–e49pmid:29440112
    OpenUrlFREE Full Text
  18. ↵
    1. Zhong VW,
    2. Juhaeri J,
    3. Mayer-Davis EJ
    . Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care 2018;41:1870–1877pmid:29386248
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Vellanki P,
    2. Umpierrez GE
    . Increasing hospitalizations for DKA: a need for prevention programs. Diabetes Care 2018;41:1839–1841pmid:30135197
    OpenUrlFREE Full Text
  20. ↵
    1. Rosenstock J,
    2. Ferrannini E
    . Euglycemic diabetic ketoacidosis: a predictable, detactable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638–1642pmid:26294774
    OpenUrlFREE Full Text
  21. ↵
    1. Watts NB,
    2. Bilezikian JP,
    3. Usiskin K, et al
    . Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157–166pmid:26580237
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kohler S,
    2. Kaspers S,
    3. Salsali A,
    4. Zeller C,
    5. Woerle HJ
    . Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care 2018;41:1809–1816pmid:29907581
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Jabbour S,
    2. Seufert J,
    3. Scheen A,
    4. Bailey CJ,
    5. Karup C,
    6. Langkilde AM
    . Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 2018;20:620–628pmid:28950419
    OpenUrlCrossRefPubMed
  24. ↵
    1. Thrailkill KM,
    2. Nyman JS,
    3. Bunn RC, et al
    . The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 2017;94:141–151pmid:27989651
    OpenUrlPubMed
    1. Blau JE,
    2. Bauman V,
    3. Conway EM, et al
    . Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 2018;3:e99123pmid:29669938
    OpenUrlPubMed
  25. ↵
    1. Bilezikian JP,
    2. Watts NB,
    3. Usiskin K, et al
    . Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 2016;101:44–51pmid:26580234
    OpenUrlCrossRefPubMed
  26. ↵
    1. Crandall CJ,
    2. Yildiz VO,
    3. Wactawski-Wende J, et al
    . Postmenopausal weight change and incidence of fracture: post hoc findings from Women’s Health Initiative Observational Study and Clinical Trials. BMJ 2015;350:h25pmid:25627698
    OpenUrlAbstract/FREE Full Text
    1. Villareal DT,
    2. Fontana L,
    3. Weiss EP, et al
    . Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 2006;166:2502–2510pmid:17159017
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Villareal DT,
    2. Fontana L,
    3. Das SK, et al.; CALERIE Study Group
    . Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial. J Bone Miner Res 2016;31:40–51pmid:26332798
    OpenUrlCrossRefPubMed
  28. ↵
    1. Bachrach LK,
    2. Guido D,
    3. Katzman D,
    4. Litt IF,
    5. Marcus R
    . Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 1990;86:440–447pmid:2388792
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Misra M,
    2. Aggarwal A,
    3. Miller KK, et al
    . Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics 2004;114:1574–1583pmid:15574617
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Cefalu WT,
    2. Riddle MC
    . SGLT2 inhibitors: the latest “new kids on the block”! Diabetes Care 2015;38:352–354pmid:25715412
    OpenUrlFREE Full Text
    1. Nathan DM
    . Adjunctive treatments for type 1 diabetes. N Engl J Med 2017;377:2390–2391pmid:28899219
    OpenUrlPubMed
  31. ↵
    1. McCrimmon RJ,
    2. Henry RR
    . AGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 2018;61:2126–2133
    OpenUrl
PreviousNext
Back to top
Diabetes Care: 41 (12)

In this Issue

December 2018, 41(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Matthew C. Riddle, William T. Cefalu
Diabetes Care Dec 2018, 41 (12) 2444-2447; DOI: 10.2337/dci18-0041

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Matthew C. Riddle, William T. Cefalu
Diabetes Care Dec 2018, 41 (12) 2444-2447; DOI: 10.2337/dci18-0041
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Prognostic Value of Time in Range in Type 2 Diabetes
  • Spontaneous or Deliberate: Effects of Acute Variations in Glycemia on Gastric Emptying in Type 1 Diabetes
  • Apps and the Woman With Gestational Diabetes Mellitus
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.